Fabio Pammolli Summarizes Research on Pharma R&D

According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, rare diseases and advanced therapies. Find out more here.

You might also be interested in:

PRMA Consulting Announces New Singapore Office and Virtual Open House 08/11/2020
Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
Stanford Center for Health Education Launches Online Program… 08/11/2020
How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
Syapse and FDA Leverage Real-World Data to Study Impact of… 10/05/2020
Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020